Clinical Stage Drug Discovery Based on Our Proprietary Platform Technology

SMNH: Delivering Novel Chemistry Solutions for Today's Diseases

SB 9200: A Potential Breakthrough Drug for HBV

Latest News

    • MAY 1, 2017

    Spring Bank Pharmaceuticals to Present at the East Coast IDEAS Investor Conference on May 18th in Boston

    HOPKINTON, Mass., May 01, 2017 (GLOBE NEWSWIRE) — Spring Bank Pharmaceuticals (NASDAQ:SBPH) today announced that Martin Driscoll, president and chief executive officer of Spring Bank Pharmaceuticals, will present at the East Coast IDEAS Investor Conference on May 18, 2017 at the Boston Park Plaza in Boston, Massachusetts. Spring Bank’s presentation is scheduled to begin at 10:00 a.m. EDT. The presentation will be webcast live and may be accessed at the conference website,, or on the “Investors & Media” page of the company’s website:  The webcast will also be archived on the “Investors & Media” page of the company’s website.

    Read more
    • APRIL 28, 2017

    Spring Bank Pharmaceuticals Provides Corporate Update and Reports First Quarter 2017 Financial and Operational Results

    Completes monotherapy dosing in first cohort of the ACHIEVE global Phase 2a clinical trial of SB 9200 in chronic HBV patients
    HOPKINTON, Mass., April 28, 2017 (GLOBE NEWSWIRE) — Spring Bank Pharmaceuticals, Inc. (Nasdaq:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, cancer, and inflammatory diseases, today provided an update on recent developments and reported financial results for the first quarter 2017.

    “We achieved a significant milestone for Spring Bank earlier this week with the final monotherapy dosing of our lead development compound, SB 9200, in the last patient of the first cohort of our ACHIEVE global Pha…

    Read more